Sana reports SC291 ARDENT interim data with responses and immune evasion; cash $205.4M

Sana Biotechnology, Inc.

Preliminary cash, cash equivalents and marketable securities as of Jan 2, 2024: approximately $205.4 million.
ARDENT interim: 4 evaluable patients; 3 partial responses including ongoing complete responses; no DLTs, GVHD, or CRS/ICANS.
HIP-edited CAR T cells evaded innate and adaptive immune responses in all 4 evaluable patients; non-HIP cells were recognized.
IND cleared for GLEAM (lupus/vasculitis) and VIVID (CD22 CAR T) trials; data expected in 2024.
Preclinical: HIP primary islets in diabetic NHP achieved insulin independence for 6 months without immunosuppression; IST of UP421 authorized.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.